Median Technologies Secures €37.5 Million Financing with EIB

Median Technologies has announced a new financing facility of up to €37.5 million with the European Investment Bank (EIB). The deal was signed on July 11, 2025, in line with earlier communications from January and April 2025. CEO Fredrik Brag expressed confidence that this agreement strengthens the company's financial standing for the commercialization of their eyonis® Lung Cancer Screening (LCS) in the U.S. and Europe.

The financing will be distributed in three tranches. Tranche A of €19 million is contingent on several conditions, including share capital increase and repayment of a previous loan. The facility will fund advancements in eyonis® for early cancer diagnosis, notably lung and liver cancers.

Applications for regulatory approval in the U.S. and Europe are already underway. Commercial discussions with AI diagnostic firms suggest significant interest, and FDA clearance could spur finalization of strategic partnerships.